A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 Years of Age
Latest Information Update: 11 Jun 2025
At a glance
- Drugs Atogepant (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Acronyms ATO EM PEDS
- Sponsors AbbVie
Most Recent Events
- 19 Dec 2024 Planned End Date changed from 4 May 2028 to 1 May 2028.
- 19 Dec 2024 Planned primary completion date changed from 30 Mar 2028 to 1 Mar 2028.
- 11 Mar 2024 Planned End Date changed from 9 May 2028 to 4 May 2028.